Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) is a commercial stage biotechnology company that primarily focuses on researching and developing stem cell treatments for sexual dysfunction, infertility, and related issues. Shares of the stem cell treatment company soared nearly 51% during trading on Wednesday, April 4, 2018. Over the past month, Creative Medical Technology Holdings, Inc. has seen average daily volume of 36.93 million shares. However, volume of 90.6 million shares or dollar volume of $724,822, exchanged hands during trading Wednesday.
Shares of Creative Medical Technology Holdings, Inc. surged on Wednesday, after the company announced new data showing its proprietary AmnioStem stem cell product demonstrated a superior immune modulatory ability relative to more traditional stem cells (bone marrow, adipose tissue, placental issue, etc.). The company generated the data from testing at its BioLabs facility in San Diego, California. Here is the full press release detailing of the data and what it means for the company moving forward:
Creative Medical Technology Holdings, Inc. Press Release:
PHOENIX, April 4, 2018 /PRNewswire/ — Creative Medical Technology Holdings (OTCQB: CELZ) announced today new data demonstrating superior immune modulatory ability of its AmnioStem™ stem cell product when compared head-to-head with bone marrow, adipose tissue, and placental tissue mesenchymal stem cells. The data, which was generated by the Company at its BioLabs research facility in San Diego, showed that AmnioStem™ cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12 as compared to other stem cells.
“Control of molecules such as TNF-alpha represents a multi-billion dollar market. Currently drugs like Humira, Remicade, and Embrel, which are antibodies blocking the TNF-alpha pathway, have sales of over $30 billion per year,” said Thomas Ichim, Ph.D, Cofounder and Chief Scientific Officer of Creative Medical Technology Holdings. “Using cells as drugs represents a more viable alternative to existing approaches because the stem cells not only reduce inflammation, but also have ability to induce healing of injured tissue.”
Dr. Ichim has taken several cell therapies to FDA clearance and clinical trials. The Company is currently preparing an Investigational New Drug (IND) application with the FDA for use of its AmnioStem™ stem cell product for treatment of radiation toxicity through its neurology focused subsidiary CerebroStem LLC and its Medical Director, Santosh Kesari, MD, Ph.D, FANA, FAAN, Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as Director of Neuro-Oncology, Providence Saint John’s Health Center and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.
“We are extremely excited about our data, which positions Creative Medical Technology Holdings as a force in the autoimmune market. In addition to treatment of stroke and radiation toxicity, autoimmune diseases that may benefit from use of AmnioStem™ technology include Type 1 Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, and Lupus,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “I am thankful for our collaborative network of scientists, scientific advisors, and intellectual property advisors, which are currently working in expanding the intellectual property portfolio surrounding this new cell type.”
The AmnioStem™ stem cell is covered by an issued US Patent that was exclusively licensed from the University of California by the Company in 2016.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
